CLINICAL IMMUNOLOGY
Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid
More details
Hide details
Submission date: 2015-11-16
Final revision date: 2015-12-22
Acceptance date: 2015-12-22
Publication date: 2017-05-08
Cent Eur J Immunol 2017;42(1):85-90
KEYWORDS
ABSTRACT
Recent studies postulated the association between bullous pemphigoid (BP) and neurodegenerative disorders (ND). The autoantibodies to BP180 and/or BP230 may be present not only in BP, but also in ND as neuronal isoforms of these proteins are identified in the central nervous system. However, there are only scant data about the precise pathogenetic mechanisms interlinking ND and BP as well as the immunologic profile in these patients. The aim is to analyze the serological immunopathological profiles (anti-BP180 IgG, anti-BP230 IgG) in BP patients with and without ND in order to identify the specific autoantibody(ies) and corresponding antigens responsible for ND development in BP patients.
Altogether, 82 ethnic Poles with BP and their medical records were examined (62 BP-ND; 20 BP+ND). Levels of serum anti-BP180/BP230 IgG in BP patients were evaluated with ELISAs. The statistical analyses involved Pearson chi-squared test, Mann-Whitney U-test and ranking of autoantibodies.
The prevalence of ND among BP patients was 24.4%. There were no statistically significant differences in autoantigens profiles (anti-BP180/anti-BP230 IgG) between BP+ND and BP-ND groups. There was no relationship between ND development and anti-BP180/anti-BP230 IgG level (p = 0.5933, p = 0.4701, respectively).
The autoantibodies levels of BP+ND and BP-ND patients show insignificant differences suggesting that also in ethnic Poles a hypothetical pathogenetic association of BP and ND, but not only an aging-related epidemiological one, appears to be independent of a particular BP antigen. Nevertheless, it cannot be excluded that phenomena of epitopes spreading, immune cross-reaction and conformational changes in BP180/BP230 may underlie BP development in ND patients.
REFERENCES (22)
1.
Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M (2012): Autoimmunity-driven enzymatic remodeling of the dermal-epidermal junction in bullous pemphigoid and dermatitis herpetiformis. Autoimmunity 45: 71-80.
2.
Lo Schiavo A, Ruocco E, Brancaccio G, et al. (2013): Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 31: 391-399.
3.
Perivier S, Trellu LT (2013): Bullous pemphigoid: a cutaneous disorder to be known in aging persons]. Rev Med Suisse 9: 2049-2053.
4.
Chen J, Li L, Chen J, et al. (2011): Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 57: 211-21.
5.
Seppänen A, Suuronen T, Hofmann SC, et al. (2007): Distribution of collagen XVII in the human brain. Brain Res 1158: 50-56.
6.
Li L, Chen J, Wang B, et al. (2009): Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 160: 1343-1345.
7.
Seppänen A (2013): Collagen XVII: a shared antigen in neurodermatological interactions? Clin Dev Immunol 2013: 240570.
8.
Bastuji-Garin S, Joly P, Lemordant P, et al. (2011): French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131: 637-643.
9.
Langan SM, Groves RW, West J (2011): The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 131: 631-636.
10.
Taghipour K, Chi CC, Bhogal B, et al. (2014): Immunopathological characteristics of patients with bullous pemphigoid and neurological disease. J Eur Acad Dermatol Venereol 28: 569-573.
11.
Tarazona MJM, Mota ANC de M, Gripp AC, et al. (2015): Bullous pemphigoid and neurological disease: statistics from a dermatology service. An Bras Dermatol 90: 280-282.
12.
Brick KE, Weaver CH, Savica R, et al. (2014): A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol 71: 1191-1197.
13.
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, et al. (2016): Bullous pemphigoid and neurodegenerative diseases: A study in a setting of a Central European university dermatology department. Aging Clin Exp Res 28: 659-663.
14.
Gambichler T, Segert H, Höxtermann S, et al. (2015): Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol 2015; 29: 1758-1762.
15.
Casas-de-la-Asunción E, Ruano-Ruiz J, Rodríguez-Martín AM, et al. (2014): Association between bullous pemphigoid and neurologic diseases: a case-control study. Actas Dermosifiliogr 105: 860-865.
16.
Taghipour K, Chi C-C, Vincent A, et al. (2010): The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010; 146: 1251-1254.
17.
Jedlickova H, Hlubinka M, Pavlik T, et al. (2010): Bullous pemphigoid and internal diseases – a case-control study. Eur J Dermatol 20: 96-101.
18.
Cordel N, Chosidow O, Hellot M-F, et al. (2007): French Study Group of Bullous Diseases. Neurological disorders in patients with bullous pemphigoid. Dermatol Basel Switz 215: 187-191.
19.
Stinco G, Codutti R, Scarbolo M, et al. (2005): A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol 85: 136-139.
20.
Gornowicz-Porowska J, Pietkiewicz P, Bowszyc-Dmochowska M, et al. (2015): Schorzenia neurodegeneracyjne a pemfigoid pęcherzowy – retrospektywne badanie immunopatologiczne (abstract). Przegląd Dermatologiczny 102: 89-90.
21.
Laffitte E, Burkhard PR, Fontao L, et al. (2005): Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 152: 537-540.
22.
Messingham K, Narayanan N, Aust N, et al. (2015): Collagen XVII autoantibodies are present in Parkinson’s Disease patients and co-localize with tyrosine hydroxylase in the substantia nigra. 2015 Annual Meeting of the SID, Atlanta, USA, 6-9 May 2015. J Invest Dermatol 135 Suppl: S14.